Sopharma AD (SPH) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Sopharma AD (SPH) has a cash flow conversion efficiency ratio of -0.019x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (zł-17.24 Million ≈ $-4.74 Million USD) by net assets (zł926.37 Million ≈ $254.95 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See SPH net asset quality score to measure how much of total assets are equity-financed.
Sopharma AD - Cash Flow Conversion Efficiency Trend (2011–2024)
This chart illustrates how Sopharma AD's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Sopharma AD earnings quality ratio to evaluate the quality of earnings relative to operating cash generation.
Sopharma AD Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Sopharma AD ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
McEwen Mining Inc.
TO:MUX
|
0.019x |
|
Suzhou Shihua New Material Technology Co Ltd
SHG:688093
|
0.030x |
|
Virtus Investment Partners, Inc.
NASDAQ:VRTS
|
0.106x |
|
MAC Copper Ltd
AU:MAC
|
0.243x |
|
Eyepoint Pharmaceuticals Inc
NASDAQ:EYPT
|
-0.297x |
|
Kunshan Kersen Science & Tech
SHG:603626
|
0.055x |
|
Marten Transport Ltd
NASDAQ:MRTN
|
0.007x |
|
Xinjiang Tianye Co Ltd
SHG:600075
|
0.109x |
Annual Cash Flow Conversion Efficiency for Sopharma AD (2011–2024)
The table below shows the annual cash flow conversion efficiency of Sopharma AD from 2011 to 2024. For the full company profile with market capitalisation and key ratios, see Sopharma AD market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | zł843.10 Million ≈ $232.03 Million |
zł76.73 Million ≈ $21.12 Million |
0.091x | +52.30% |
| 2023-12-31 | zł753.63 Million ≈ $207.41 Million |
zł45.03 Million ≈ $12.39 Million |
0.060x | -65.57% |
| 2022-12-31 | zł718.13 Million ≈ $197.64 Million |
zł124.62 Million ≈ $34.30 Million |
0.174x | +250.52% |
| 2021-12-31 | zł658.87 Million ≈ $181.33 Million |
zł-75.96 Million ≈ $-20.91 Million |
-0.115x | +63.59% |
| 2020-12-31 | zł566.60 Million ≈ $155.94 Million |
zł-179.41 Million ≈ $-49.38 Million |
-0.317x | -41.94% |
| 2019-12-31 | zł575.77 Million ≈ $158.46 Million |
zł-128.44 Million ≈ $-35.35 Million |
-0.223x | -500.25% |
| 2018-12-31 | zł508.53 Million ≈ $139.95 Million |
zł28.34 Million ≈ $7.80 Million |
0.056x | -29.89% |
| 2017-12-31 | zł503.11 Million ≈ $138.46 Million |
zł40.00 Million ≈ $11.01 Million |
0.080x | -22.88% |
| 2016-12-31 | zł491.22 Million ≈ $135.19 Million |
zł50.64 Million ≈ $13.94 Million |
0.103x | +121.34% |
| 2015-12-31 | zł457.64 Million ≈ $125.95 Million |
zł21.31 Million ≈ $5.87 Million |
0.047x | -0.37% |
| 2014-12-31 | zł431.64 Million ≈ $118.79 Million |
zł20.18 Million ≈ $5.55 Million |
0.047x | -34.03% |
| 2013-12-31 | zł412.77 Million ≈ $113.60 Million |
zł29.25 Million ≈ $8.05 Million |
0.071x | -21.21% |
| 2012-12-31 | zł391.35 Million ≈ $107.71 Million |
zł35.20 Million ≈ $9.69 Million |
0.090x | -14.33% |
| 2011-12-31 | zł365.81 Million ≈ $100.68 Million |
zł38.40 Million ≈ $10.57 Million |
0.105x | -- |
About Sopharma AD
Sopharma AD produces, distributes, and exports pharmaceutical products in Europe, Bulgaria, and internationally. It offers Carsil to treat liver disease; Tempalgin, a painkiller; Analgin, a pain reliever; Tabex, a drug used for smoking secession; Tribestan, a drug used for stimulation of the male reproductive system; Broncholytin, which is used to suppress cough; Nivalin for use in the peripheral… Read more